Electromed (ELMD) LD Micro 20th Annual Main Event Conference summary

Business profile and performance

• Founded in 1992, Minnesota-based, with ~200 employees; FY and Q4 results were records, with profitability, cash generation, no debt, and improving operating leverage.

• Revenue was ~$75 million, with gross margin in the high 70s; share price rose from ~$10.60 to ~$28 over three years, alongside higher operating income and EPS.

• CEO Jim Cunniff announced plans to retire in April 2027 after reporting record FY results.

Market and treatment opportunity

• Bronchiectasis is chronic and irreversible; ~1 million people in the U.S. have the condition, while ~166,000 use HFCWO technology.

• The estimated U.S. opportunity is $3.1 billion, based on untreated patients seen by pulmonologists and an average device sale price of ~$10,500; 4.1 million people with COPD-bronchiectasis overlap could potentially double the market.

• Treatment combines airway clearance, antibiotics for infection, and inflammation reduction; patients typically use airway-clearance technology at home twice daily for ~15 minutes per session.

• No cure is on the horizon; treatment aims to clear mucus and improve quality of life for patients with irreversible airway widening.

SmartVest and care model

• SmartVest uses high-frequency chest wall oscillation to move mucus into larger airways; the vest is lightweight, uses a single hose, and is designed for routine home use.

• Direct-to-patient operations include manufacturing, payer contracts covering 87% of U.S. lives, home delivery, and respiratory-therapist training; rental billing runs 10–13 months, after which patients own the device with a lifetime warranty.

• Patient feedback included 94% willing to recommend SmartVest and 97% feeling better or the same; reported outcomes included 59% fewer hospitalizations and 75% fewer ED visits.

• Home care generated 94% of revenue, hospitals ~5%, and OUS a small share; payer mix was ~50% Medicare and ~50% private payers, with gross margin in the high 70s versus competitors' margins in the 50s.